Zynex Inc. (ZYXI) Stock Rating Upgraded by Zacks Investment Research

Zynex Inc. (OTCMKTS:ZYXI) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Thursday. The firm currently has a $3.25 price target on the stock. Zacks Investment Research‘s price objective would suggest a potential upside of 8.33% from the company’s previous close.

According to Zacks, “Zynex, Inc. engineers, manufactures, markets, and sells medical devices for the electrotherapy, and stroke and spinal cord injury rehabilitation markets primarily in the United States. The company primarily offers electrotherapy products for pain relief and pain management; and NeuroMove for stroke and spinal cord injury rehabilitation. The company’s product lines are fully developed, FDA-cleared, commercially sold, and have been developed to uphold the Company’s mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain. Zynex markets its products through commissioned and independent sales representatives, as well as directly to end users through advertisements and articles in relevant publications and on the Internet. The company is headquartered in Littleton, Colorado. “

A number of other research firms also recently issued reports on ZYXI. ValuEngine raised shares of Zynex from a “hold” rating to a “buy” rating in a research note on Wednesday, August 23rd. Taglich Brothers reaffirmed a “speculative buy” rating on shares of Zynex in a research note on Monday, August 21st.

Zynex (OTCMKTS:ZYXI) opened at $3.00 on Thursday. Zynex has a 1-year low of $0.25 and a 1-year high of $3.25. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.27 and a quick ratio of 1.19. The company has a market cap of $99.81, a price-to-earnings ratio of 23.39 and a beta of -0.03.

Zynex (OTCMKTS:ZYXI) last released its earnings results on Monday, November 13th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.06 by $0.01. Zynex had a net margin of 24.10% and a negative return on equity of 248.78%. The firm had revenue of $6.82 million for the quarter, compared to the consensus estimate of $5.52 million. research analysts expect that Zynex will post 0.17 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Zynex Inc. (ZYXI) Stock Rating Upgraded by Zacks Investment Research” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.com-unik.info/2017/11/25/zynex-inc-zyxi-stock-rating-upgraded-by-zacks-investment-research.html.

About Zynex

Zynex, Inc operates through the Electrotherapy and Pain Management Products segment. The Company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc (ZMI). Its other subsidiaries include Zynex Monitoring Solutions, Inc (ZMS) and Zynex Europe, ApS (ZEU). ZMI designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation.

What are top analysts saying about Zynex Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zynex Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit